Scientific Approach
Pipeline
INBRX-109
INBRX-106
INBRX-105
INBRX-101
Investors
Patients
Partners
Who We Are
Team
Contact Us
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Apr 1, 2025
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Mar 17, 2025
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Jan 21, 2025
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Jan 13, 2025
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
Nov 14, 2024
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
16
»
